Palatin Receives $4.7 Million of Non-Dilutive Funding
Palatin Technologies (PTN) has secured approximately $4.7 million in non-dilutive funding through New Jersey's Net Operating Loss (NOL) Program. This program enables qualified technology companies to convert state operating losses into cash. To date, Palatin has received about $18 million from this program. CFO Stephen T. Wills expressed gratitude for the support from the NJ Economic Development Authority, highlighting the funding's role in advancing drug development efforts. Palatin focuses on creating first-in-class medicines targeting the melanocortin receptor system, aiming to address significant unmet medical needs.
- Secured approximately $4.7 million in non-dilutive funding.
- Total funding received through the NOL program now totals around $18 million.
- None.
Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
"We are pleased to take advantage of the New Jersey NOL program which allows us to convert certain state operating losses into tangible working capital today," said
The NOL program enables qualified, NJ-based technology or biotechnology companies to sell net operating losses to unrelated profitable corporations. This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development or other allowable expenditures.
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor- specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Statements in this press release that are not historical facts, including statements about future expectations of Palatin, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the
Palatin Technologies® is a registered trademark of
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-receives-4-7-million-of-non-dilutive-funding-301724397.html
SOURCE
FAQ
What amount of funding did Palatin Technologies receive through the New Jersey NOL program?
How much total funding has Palatin Technologies received from the NOL program to date?
What is the purpose of New Jersey's Net Operating Loss program for Palatin Technologies?
What is the focus of Palatin Technologies in drug development?
